Clinical trial
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for…
NCT00214838 · Callisto Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00214838 |
|---|---|
| Title | An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer |
| Official title | An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer |
| Lead sponsor | Callisto Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Cancer |
| Intervention type | Drug |
| Interventions | Atiprimod |
| Enrollment | 61 |
| Start date | Mar 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 5, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: